United States: FDA Draft Guidances On General Wellness Products And Device Accessories Continue Risk-Based Approach To Health IT

On January 20, 2015, the United States Food and Drug Administration (FDA) issued two new draft guidance documents, announcing the agency's plans not to regulate "general wellness products" (including certain software programs) and to apply a new, risk-based framework to medical device accessories. Although not limited to the health IT sphere, both draft guidance documents address issues identified as requiring clarification in the April 2014 FDASIA Health IT Report. These draft guidance documents are consistent with the risk-based approach to regulation described in the FDASIA Health IT report, and which is reflected in FDA's final guidance on Mobile Medical Apps and draft guidance on Medical Device Data Systems. Just days later, FDA applied the accessory policy by allowing the marketing of the first set of mobile medical apps for automatically sharing data from a continuous glucose monitor (CGM) in real-time using an Apple mobile device such as an iPhone.

General Wellness Product Draft Guidance

According to the draft guidance, FDA will not apply either pre- or post-market regulatory requirements to "general wellness products" that pose a low risk to a user's safety. Examples of such products include software programs, exercise equipment, audio recordings, video games, and other products commonly available from retail establishments or downloaded from online sources. General wellness products, for the purposes of the guidance, must fall into one of two categories, based on intended use. The intended use must either:

  1. relate to maintaining or encouraging a general state of health or a healthy activity, without any reference to particular diseases or conditions, or 
  2. associate the role of a healthy lifestyle with helping to reduce the risk of impact of certain chronic diseases or conditions, where it is well accepted that the healthy lifestyle choices may play an important role in health outcomes for the disease or condition.

The first category applies to products that encourage a general state of health or a healthy activity, but do not make any reference to particular diseases or conditions. Such products might promote, for example, weight management, stress management, or sexual function, but without referring to particular diseases such as obesity, anxiety disorders, or erectile dysfunction. 

The second category addresses products to promote, track, or encourage choices that, as part of a healthy lifestyle, "may help reduce the risk of" or "may help living well with" certain chronic diseases or conditions. This category would apply, for example, to a software app that claims to promote physical activity, which, as part of a healthy lifestyle, may help reduce the risk of high blood pressure. 

For both categories, the product must meet additional "low risk" criteria. It may not be "invasive" (i.e., may not penetrate or pierce the skin or mucous membranes), involve an intervention that may pose a risk to user safety (e.g., lasers, radiation exposure), raise novel questions of usability, or raise questions of biocompatibility. 

Medical Device Accessory Draft Guidance

The definition of a "device" under the Federal Food, Drug, and Cosmetic Act includes any "accessory" to a device. Medical devices are assigned to one of three regulatory classes based on the level of control needed to provide reasonable assurance of their safety and effectiveness. FDA's longstanding policy has been that an accessory to a classified device takes on the same classification as the "parent" device, which can lead to relatively low-risk accessories taking on the higher classification of the parent. 

Under this policy, for example, software that accepts inputs from a medical device usually takes on the classification of the connected device, or a simple surgical instrument labeled for use with a Class II medical device implant system usually takes on the classification of the implant system, even though these accessories might be relatively simple and lower-risk than the parent devices. In the Mobile Medical Apps guidance, FDA stated that a mobile app used as an accessory to a regulated device would be considered a "mobile medical app" potentially subject to FDA regulation, but did not address FDA's approach to regulating them.

Under the draft guidance, FDA acknowledges that accessories are not always as risky as the parent devices with which they are intended to work. It therefore proposes to determine the risk of accessories, and the regulatory controls applicable to them, in the same manner it determines the classification of devices that are not accessories. FDA states that it will not impute all the risks of the parent device to the accessory, but instead will evaluate the accessory's impact on the parent device and any unique risks of the accessory independent of the parent device. This marks a potentially significant shift in FDA regulatory policy.

The draft guidance urges companies to rely on the de novo classification process under Section 513(f)(2) of the FDCA to request classification of new types of accessories, and provides additional details for how to file a de novo request for a new type of accessory. The key advantage of the de novo process is that an accessory may be marketed immediately if FDA classifies the accessory into Class I or II. The de novo process, however, may not be appropriate for certain accessories, specifically those accessories within a type of device that has already been classified by regulation or order or has received premarket approval. In such cases, a company may instead seek reclassification or an exemption from the requirement to submit a 510(k) premarket notification.

The draft guidance also sets out a proposed definition of "accessory." This is FDA's first detailed explanation of its understanding of that term, which has been in the statute since the enactment of the Medical Device Amendments of 1976. Although the practice of defining such a key regulatory term through a guidance document rather than a regulation may be questionable, industry will likely welcome the additional transparency on FDA's interpretation of this term.

As explained in the draft guidance, an article is an accessory to a device if it is intended to "support, supplement, and/or augment the performance of one or more parent devices," and a "parent" device is a "finished device whose performance is supported, supplemented, and/or augmented by one or more accessories." FDA explains that whether an article is intended for use with a parent device will generally be determined by the labeling and promotional materials for the potential accessory, rather than by the labeling and promotional materials for the parent device. FDA also points out that articles that do not meet the definition of an accessory will not be treated as accessories simply because they may be used in conjunction with a medical device. Thus, for example, an off-the-shelf computer monitor used to display medical data from connected medical devices would not be considered an accessory to those devices unless it was intended for that use.

On January 23, FDA demonstrated how the accessory policy will work by allowing the marketing of a set of mobile medical apps that permit the sharing of data from a continuous glucose monitor (CGM) with others in real-time using an Apple mobile device such as an iPhone. These apps would meet the definition of an accessory to the CGM devices and thus, under FDA's traditional policy, require the same form of 510(k) premarket clearance that FDA requires for CGMs. Instead, FDA has applied its de novo authority to allow such devices to be marketed as 510(k)-exempt, meaning no FDA premarket notification is required.

What's Next?

These latest FDA draft guidances, although they have implications beyond health IT, contribute to FDA's efforts to clarify its policies across the range of health IT applications and products. In addition to accepting comments on these draft guidance and eventually finalizing them, one of the key outstanding items that FDA has announced it is developing is a draft guidance on clinical decision support (CDS) tools. In the FDASIA Health IT Report, FDA proposed to exercise enforcement discretion not to regulate "most" CDS tools, but stated that it would regulate a "subset" of CDS tools as medical devices. How FDA defines that subset of CDS products will have important implications for the future regulation of software that can be used to help determine treatment options for patients. The first three draft guidance topics that FDA's Center for Devices and Radiological Health listed on its FY2015 "A-list" were General Wellness Products, Medical Device Accessories, and Medical Device Decision Support Software. With the first two of these guidances now published in draft, the CDS draft guidance may not be far behind.

Developers of health-related software also should understand that FDA is not the only potential regulator of their products. A recent Federal Trade Commission (FTC) action against Focus Education, a company that claimed its video games lessen the symptoms of Attention Deficit Hyperactivity Disorder, shows the importance of ensuring that all claims of health-related benefits are well substantiated. The FDA, FTC, or state agencies all may have authority to take action against companies that promote software for unproven health-related benefits.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions